Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia

Lisa Richter, Yiqian Wang, Ricia K Hyde

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Inversion of chromosome 16 (inv(16)) generates the CBFβ-SMMHC fusion protein and is found in nearly all patients with acute myeloid leukemia subtype M4 with Eosinophilia (M4Eo). Expression of CBFβ-SMMHC is causative for leukemia development, but the molecular mechanisms underlying its activity are unclear. Recently, there have been important advances in defining the role of CBFβ-SMMHC and its binding partners, the transcription factor RUNX1 and the histone deacetylase HDAC8. Importantly, initial trials demonstrate that small molecules targeting these binding partners are effective against CBFβ-SMMHC induced leukemia. This review will discuss recent advances in defining the mechanism of CBFβ-SMMHC activity, as well as efforts to develop new therapies for inv(16) AML.

Original languageEnglish (US)
Pages (from-to)66255-66266
Number of pages12
JournalOncotarget
Volume7
Issue number40
DOIs
StatePublished - 2016

Fingerprint

Chromosomes, Human, Pair 16
Acute Myeloid Leukemia
Leukemia
Leukemia, Myelomonocytic, Acute
Histone Deacetylases
Eosinophilia
Proteins
Transcription Factors
Therapeutics

Keywords

  • AML
  • CBFß
  • CBFβ-SMMHC
  • Inv(16)
  • RUNX1

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia. / Richter, Lisa; Wang, Yiqian; Hyde, Ricia K.

In: Oncotarget, Vol. 7, No. 40, 2016, p. 66255-66266.

Research output: Contribution to journalArticle

@article{152940d8c6f34c6d94239d4aa8c31f34,
title = "Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia",
abstract = "Inversion of chromosome 16 (inv(16)) generates the CBFβ-SMMHC fusion protein and is found in nearly all patients with acute myeloid leukemia subtype M4 with Eosinophilia (M4Eo). Expression of CBFβ-SMMHC is causative for leukemia development, but the molecular mechanisms underlying its activity are unclear. Recently, there have been important advances in defining the role of CBFβ-SMMHC and its binding partners, the transcription factor RUNX1 and the histone deacetylase HDAC8. Importantly, initial trials demonstrate that small molecules targeting these binding partners are effective against CBFβ-SMMHC induced leukemia. This review will discuss recent advances in defining the mechanism of CBFβ-SMMHC activity, as well as efforts to develop new therapies for inv(16) AML.",
keywords = "AML, CBF{\ss}, CBFβ-SMMHC, Inv(16), RUNX1",
author = "Lisa Richter and Yiqian Wang and Hyde, {Ricia K}",
year = "2016",
doi = "10.18632/oncotarget.11357",
language = "English (US)",
volume = "7",
pages = "66255--66266",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

TY - JOUR

T1 - Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia

AU - Richter, Lisa

AU - Wang, Yiqian

AU - Hyde, Ricia K

PY - 2016

Y1 - 2016

N2 - Inversion of chromosome 16 (inv(16)) generates the CBFβ-SMMHC fusion protein and is found in nearly all patients with acute myeloid leukemia subtype M4 with Eosinophilia (M4Eo). Expression of CBFβ-SMMHC is causative for leukemia development, but the molecular mechanisms underlying its activity are unclear. Recently, there have been important advances in defining the role of CBFβ-SMMHC and its binding partners, the transcription factor RUNX1 and the histone deacetylase HDAC8. Importantly, initial trials demonstrate that small molecules targeting these binding partners are effective against CBFβ-SMMHC induced leukemia. This review will discuss recent advances in defining the mechanism of CBFβ-SMMHC activity, as well as efforts to develop new therapies for inv(16) AML.

AB - Inversion of chromosome 16 (inv(16)) generates the CBFβ-SMMHC fusion protein and is found in nearly all patients with acute myeloid leukemia subtype M4 with Eosinophilia (M4Eo). Expression of CBFβ-SMMHC is causative for leukemia development, but the molecular mechanisms underlying its activity are unclear. Recently, there have been important advances in defining the role of CBFβ-SMMHC and its binding partners, the transcription factor RUNX1 and the histone deacetylase HDAC8. Importantly, initial trials demonstrate that small molecules targeting these binding partners are effective against CBFβ-SMMHC induced leukemia. This review will discuss recent advances in defining the mechanism of CBFβ-SMMHC activity, as well as efforts to develop new therapies for inv(16) AML.

KW - AML

KW - CBFß

KW - CBFβ-SMMHC

KW - Inv(16)

KW - RUNX1

UR - http://www.scopus.com/inward/record.url?scp=84994157662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994157662&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11357

DO - 10.18632/oncotarget.11357

M3 - Article

VL - 7

SP - 66255

EP - 66266

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -